Fate Therapeutics (FATE) Long-Term Debt Issuances (2013 - 2014)
Fate Therapeutics' (FATE) quarterly Long-Term Debt Issuances came in at $10.0 million in Q4 2014, down 51.77% on a QoQ basis from $20.7 million in Q3 2013.
Powered by 
Analysis
Fate Therapeutics (FATE) Long-Term Debt Issuances (2013 - 2014) Analysis & Trends
Fate Therapeutics (FATE) has 2 years of Long-Term Debt Issuances data on file, last reported at $10.0 million in Q4 2014.
- Quarterly Long-Term Debt Issuances changed N/A year-over-year to $10.0 million in Q4 2014, while the trailing twelve-month figure through Dec 2017 was $10.0 million (changed N/A YoY) and the FY2017 annual result came in at $15.0 million, up 50.0% from the prior year.
- Long-Term Debt Issuances declined to $10.0 million in Q4 2014, from $20.7 million in the prior quarter.
- In the past five years, Long-Term Debt Issuances ranged from a high of $20.7 million in Q3 2013 to a low of $10.0 million in Q4 2014.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Fate Therapeutics | 299.79 Mn | 299.79 Mn | - | - |